Close Menu

cancer panel

BioSequence is looking to raise the profile of its genomic offering among clinicians, and to strengthen its case for reimbursement.

 

The researchers suggested that Ashkenazi Jewish women as well as women of other ancestries might benefit from broader genetic screening for breast cancer risk.

Through prospective pancreatic ductal adenocarcinoma testing, researchers saw germline mutations in new genes and in cases outside of current germline testing criteria.

A partnership involving Heidelberg University Hospital, the National Center for Tumor Diseases, and the German Cancer Research Institute is serving patients across Germany.

The company said the revenue decline was expected and related to the timing of R&D projects with biopharmaceutical partners.

The study was conducted by the European Molecular Genetics Quality Network and its partners, and involved 227 labs for germline testing and 76 for somatic testing.

More than a third of the first 10,000 patients receiving MSK-IMPACT harbored actionable mutations, and 11 percent of the first 5,000 enrolled in a clinical trial. 

The JV, called Maqgen, will be based in Chengdu, Sichuan Province, and is owned 60 percent by Maccura and 40 percent by Qiagen.

Respondents to a 2013 survey described changes in the way hereditary breast and ovarian cancer risk is assessed, interpreted, and conveyed to patients following the court decision.

Thermo is launching a program to develop its NGS Oncomine products into companion diagnostics, with the University Hospital Basel as its first partner.

Pages

In PLOS this week: transcriptomic and genomic analysis of prostate cancer by ancestry, genes linked to liver function in Korean cohort, and more.

British Columbia is incorporating genomics into its tracking of the ongoing COVID-19 outbreak, Business in Vancouver reports.

An analysis by the Personalized Medicine Coalition finds that about a quarter of new drugs approved in 2019 by the US Food and Drug Administration were personalized medicines.

The governor of New York has proposed a five-year plan to study the genomes of people with or who are at high risk of developing Alzheimer's disease.